Teclistamab is humanized immunoglobulin (Ig) G4, lambda bispecific antibody targeted on CD3 receptor expressed on the surface of T cell and B-cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells. As Teclistamab binding both targets, it is able to draw T cell expressed CD3 in close proximity to target cells expressed BCMA, resulting in T cell activation and T cell-mediated cytotoxincity, which ultimately promotes the lysis and death of BCMA expressed cell.
Product name | Teclistamab Biosimilar |
Species | Homo sapiens |
Expression system | CHO-K1 |
Buffer | PBS, pH 7.4 |
Delivery condition | Dry ice (-80°C) |
Delivery Time | 1 week if in stock; 4 weeks if production needed |
Storage condition | Store at -80°C |
Brand | BioMetas |
Applications | ELISA, assay, in vivo |
Aliases/Synonyms | Tecvayli, JNJ-63483043, JNJ-64007957, JNJ-7957 |
Reference | |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG4, λ |
Clonality | Monoclonal Antibody |
Size | 1mg, 5mg, 10mg, 50mg, 100mg |
Brand | BioMetas |
Product type | Biosimilar |
Clonality | Monoclonal Antibody |
Expression system | CHOK1 |
Applications | Elisa, assay, in vivo |
Fig. 1.) 4-20% SDS-PAGE analysis
Recombinant protein was visualized by Coomassie Brilliant Blue R250 staining.
Fig. 2.) SEC-HPLC analysis
Column: Superdex 200 Increase 5/150 GL
Running buffer: 2xPBS, pH 7.4